Logo

SMTI

Sanara MedTech Inc.

SMTI

Sanara MedTech Inc. • NASDAQ
$20.92 ▲ 0.77% (+0.16)
Market Cap $186.92 M
52w High $38.68
52w Low $18.90
Dividend Yield 0%
P/E -29.06
Volume 22.80K
Outstanding Shares 8.94M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $26.334M ▲ $21.518M ▼ $-30.411M ▼ -115.483% ▼ $0.1 ▲ $-27.982M ▼
Q2-2025 $25.831M ▲ $23.925M ▲ $-2.014M ▲ -7.798% ▲ $-0.23 ▲ $1.083M ▲
Q1-2025 $23.434M ▼ $23.679M ▼ $-3.527M ▼ -15.051% ▼ $-0.41 ▼ $-1.086M ▼
Q4-2024 $26.305M ▲ $24.431M ▲ $-1.539M ▲ -5.849% ▲ $-0.18 ▲ $1.197M ▲
Q3-2024 $21.672M $21.604M $-2.858M -13.187% $-0.34 $-243.154K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $14.94M ▼ $71.089M ▼ $64.948M ▲ $6.141M ▼
Q2-2025 $16.959M ▼ $98.768M ▲ $63.376M ▲ $35.399M ▼
Q1-2025 $20.688M ▲ $96.379M ▲ $59.711M ▲ $36.671M ▼
Q4-2024 $15.878M ▼ $88.092M ▼ $49.18M ▲ $39.404M ▼
Q3-2024 $16.277M $88.545M $49.091M $39.784M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $833.537K ▲ $2.176M ▼ $-3.421M ▲ $-774.749K ▲ $-2.019M ▲ $1.117M ▲
Q2-2025 $-2.014M ▲ $2.664M ▲ $-3.928M ▲ $-2.465M ▼ $-3.729M ▼ $902.652K ▲
Q1-2025 $-3.527M ▼ $-1.999M ▼ $-5.18M ▼ $11.988M ▲ $4.81M ▲ $-3.722M ▼
Q4-2024 $-1.701M ▲ $932.047K ▼ $-129.994K ▲ $-1.201M ▼ $-398.894K ▼ $836.423K ▼
Q3-2024 $-2.883M $2.05M $-6.357M $14.433M $10.127M $2.041M

Revenue by Products

Product Q3-2023Q4-2023Q2-2024Q2-2025
SaaS
SaaS
 $0 ▲$0 ▲$0 ▲$0 ▲
Royalty
Royalty
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Sanara MedTech shows a clear growth story on the top line, with revenue and gross profit trending upward over the last several years. The business has moved from very small sales to a more meaningful base, and margins at the gross profit level look solid for a company of its size. However, the company is still hovering around break-even at the operating and net income levels, with small losses reappearing in the most recent year after being close to breakeven before. Earnings per share remain negative and somewhat bumpy year to year. Overall, the income statement tells a story of a growing, higher-margin niche business that has not yet fully scaled to consistent profitability.

Balance Sheet

Balance Sheet The balance sheet shows a gradually expanding asset base, suggesting the company has been investing in its growth. Equity has also climbed, which is a positive sign that the business has been built up rather than heavily drained. Cash levels are modest but present, and the company has introduced some debt in recent years, though it does not appear excessive relative to the size of the business. The structure looks typical of a small, growth-focused healthcare company: not over-levered, but not flush with excess cash either, and dependent on continued growth or capital access to support its plans.

Cash Flow

Cash Flow Cash generation is close to break-even. Operating cash flow has hovered around zero, dipping negative in one of the recent years but otherwise roughly balancing inflows and outflows. Free cash flow follows a similar pattern, reflecting limited capital spending and an asset-light model. This means the company is not burning large amounts of cash, but it also is not yet producing strong, self-funding cash surpluses. The stability in cash flow is encouraging, yet it leaves limited room for major independent expansion without continued careful capital management or external funding options.

Competitive Edge

Competitive Edge Sanara MedTech operates in a focused niche within surgical and advanced wound care, where specialized products and clinical outcomes matter more than pure scale. Its portfolio of collagen-based products, antimicrobial irrigation solutions, tissue repair grafts, and regenerative biologics gives it a differentiated, procedure-oriented offering. The company’s strategy of serving surgeons across the full wound-healing process—cleaning, promoting healing, and protecting tissue—helps create a “one-stop” solution that can deepen relationships with hospitals and surgical centers. A growing network of direct reps and distributors expands reach, but Sanara still competes against much larger medical technology players with broader product lines and entrenched hospital contracts. Its edge stems from specialization, clinically oriented products, and a clear commercial focus rather than size.

Innovation and R&D

Innovation and R&D Innovation is a central part of Sanara’s story. The company’s core technologies in hydrolyzed collagen, advanced surgical irrigation, and extracellular matrix grafts give it distinct product features that aim to accelerate healing and reduce complications. Importantly, Sanara has strengthened its intellectual property position through licenses and acquisitions, including exclusive rights to a broad set of patented collagen peptides that could underpin future generations of wound and surgical products. The acquisition of Precision Healing adds a more digital and diagnostic dimension, with the potential to bring imaging and biomarker-based tools into wound care, enabling more personalized and data-driven treatment. The opportunity is meaningful, but execution risk is real: integrating acquired technologies, navigating regulatory paths, proving clinical and economic value, and successfully commercializing new offerings will all be critical to realizing the potential of this R&D pipeline.

Summary

Sanara MedTech is a small but growing healthcare company positioned in the specialized area of surgical and advanced wound care. Its financials show steady revenue growth and healthy gross margins, but profitability and cash generation are still fragile and near break-even, reflecting ongoing investment and limited scale. The balance sheet appears reasonable for a company of its size, with manageable debt and gradually building equity, but not a large cash cushion. Competitively, Sanara leans on focused, differentiated products and a comprehensive surgical offering rather than sheer size, operating in a market dominated by bigger medtech firms. Its real upside hinges on innovation: proprietary collagen technologies, biologics, and emerging diagnostic tools provide a credible platform for future products and deeper clinical integration. Overall, the company looks like an emerging niche player transitioning from early-stage growth toward scale, with clear technological strengths but also the usual execution, adoption, and funding risks that come with that stage of development.

NEWS

November 24, 2025 · 1:59 PM UTC

INVESTOR ALERT: Investigation of Sanara MedTech Inc. (SMTI) Announced by Holzer & Holzer, LLC

Read more

November 20, 2025 · 4:20 PM UTC

Securities Fraud Investigation Into Sanara MedTech Inc. (SMTI) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Read more

November 20, 2025 · 9:00 AM UTC

Sanara MedTech Inc. (SMTI) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Read more

November 19, 2025 · 5:04 PM UTC

Securities Fraud Investigation Into Sanara MedTech Inc. (SMTI) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz

Read more

November 19, 2025 · 7:30 AM UTC

Sanara MedTech to Participate in the Piper Sandler 37th Annual Healthcare Conference on December 3rd

Read more